Irisys to manufacture Qualigen COVID-19 drug

By The Science Advisory Board staff writers

Qualigen Therapeutics has signed a contract with Irisys for the production of AS1411, Qualigen's lead candidate for the treatment of viral diseases including COVID-19.

AS1411 is a DNA-coated gold nanoparticle that targets and binds nucleolin, a protein that plays a role in how viruses attack and utilize cells for replication. Preclinical studies, conducted at University of Louisville's Center for Infectious Disease, showed that AS1411 protected cells from the damaging effects of SARS-CoV-2 by binding nucleolin.

In June 2020, Qualigen signed an exclusive license agreement with the university to complete investigational new drug-enabling studies with the U.S. Food and Drug Administration in the fourth quarter of 2020. The company intends to begin phase I/II clinical studies in COVID-19 patients early next year.

Irisys is a contract pharmaceutical product development and manufacturing organization headquartered in San Diego.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: